Bio Techne Company Top Insiders

TECH Stock  USD 75.01  0.24  0.32%   
Bio Techne's insiders are aggressively selling. The analysis of insiders' sentiment of trading Bio Techne Corp stock suggests that almost all insiders are panicking at this time. Bio Techne employs about 3.1 K people. The company is managed by 24 executives with a total tenure of roughly 42 years, averaging almost 1.0 years of service per executive, having 129.17 employees per reported executive.
Charles Kummeth  CEO
CEO and President and Director

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-01-27Kim KeldermanDisposed 13392 @ 77.29View
2024-03-07Roeland NusseDisposed 10400 @ 76.98View
Monitoring Bio Techne's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Bio Techne's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bio Techne's future performance. Based on our forecasts, it is anticipated that Bio will maintain a workforce of under 3100 employees by March 2025.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Bio Techne Management Team Effectiveness

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0729 %, meaning that it created $0.0729 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Techne's current Return On Tangible Assets is estimated to increase to 0.16, while Return On Capital Employed is projected to decrease to 0.09. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 745.5 M, while Other Assets are projected to decrease to under 8.8 M.
The Bio Techne's current Net Income Applicable To Common Shares is estimated to increase to about 344.5 M, while Common Stock Shares Outstanding is projected to decrease to under 169.2 M.

Bio Techne Workforce Comparison

Bio Techne Corp is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 31,299. Bio Techne holds roughly 3,100 in number of employees claiming about 10% of equities under Health Care industry.

Bio Techne Profit Margins

The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.18.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.560.6
Significantly Down
Pretty Stable
Net Profit Margin0.190.13
Way Up
Pretty Stable
Operating Profit Margin0.260.16
Way Up
Slightly volatile
Pretax Profit Margin0.270.14
Way Up
Slightly volatile
Return On Assets0.06790.0715
Notably Down
Slightly volatile
Return On Equity0.08880.0934
Notably Down
Slightly volatile

Bio Techne Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Techne insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.3333
1
3
 13,392 
 26,784 
2024-12-01
3.8
19
5
 97,489 
 35,246 
2024-09-01
1.6429
23
14
 464,370 
 219,267 
2024-06-01
1.0
4
4
 8,549 
 11,006 
2024-03-01
3.5
7
2
 127,860 
 11,511 
2023-12-01
11.0
22
2
 210,231 
 80,255 
2023-09-01
2.3077
30
13
 580,918 
 255,610 
2023-06-01
0.6667
4
6
 643,382 
 1,028,479 
2023-03-01
0.1429
1
7
 407,364 
 687,961 
2022-12-01
6.0
18
3
 17,874 
 15,700 
2022-09-01
1.0526
20
19
 502,817 
 295,508 
2022-06-01
0.4
2
5
 5,404 
 17,312 
2022-03-01
2.6667
8
3
 16,508 
 3,726 
2021-12-01
0.8148
22
27
 44,758 
 78,245 
2021-09-01
0.5075
34
67
 287,899 
 284,983 
2021-06-01
0.1429
3
21
 48,458 
 102,196 
2021-03-01
0.3214
9
28
 109,930 
 192,003 
2020-12-01
0.5472
29
53
 104,059 
 189,976 
2020-09-01
1.1111
30
27
 355,299 
 112,119 
2020-06-01
0.3824
13
34
 82,659 
 155,110 
2020-03-01
0.2857
4
14
 43,118 
 87,623 
2019-12-01
0.875
28
32
 105,187 
 164,217 
2019-09-01
1.75
28
16
 410,116 
 145,429 
2019-06-01
0.8571
6
7
 77,467 
 56,028 
2018-09-01
0.9583
23
24
 338,083 
 105,331 
2018-06-01
1.5
3
2
 15,000 
 9,136 
2018-03-01
0.3333
1
3
 5,000 
 10,000 
2017-12-01
13.0
39
3
 459,392 
 10,100 
2017-09-01
0.2857
2
7
 76,097 
 2,483 
2017-06-01
0.2222
2
9
 10,000 
 21,359 
2017-03-01
0.125
1
8
 1,667 
 86,100 
2016-12-01
4.0
16
4
 39,192 
 1,300 
2016-09-01
1.9333
29
15
 571,372 
 23,643 
2016-06-01
0.1667
1
6
 5,000 
 10,800 
2016-03-01
0.4286
3
7
 16,666 
 27,322 
2015-09-01
5.7143
40
7
 451,536 
 22,475 
2015-06-01
0.3333
1
3
 385.00 
 1,694 
2015-03-01
0.6
3
5
 8,166 
 13,732 
2014-12-01
3.0
21
7
 53,591 
 11,182 
2014-09-01
4.0
12
3
 219,089 
 15,000 
2014-06-01
2.2
11
5
 112,181 
 9,907 
2014-03-01
0.625
5
8
 25,000 
 50,000 
2013-12-01
2.3
23
10
 75,000 
 70,000 
2013-09-01
1.75
7
4
 85,567 
 5,712 
2012-12-01
2.75
11
4
 61,012 
 34,012 
2012-09-01
1.3333
4
3
 3,753 
 1,376 
2012-03-01
0.4
4
10
 6,385,056 
 15,162,189 
2011-12-01
3.3333
10
3
 43,000 
 32,350 
2011-06-01
0.5385
7
13
 20,505 
 47,650 
2010-12-01
1.3333
12
9
 68,000 
 55,031 
2010-09-01
1.0
4
4
 14,034 
 21,039 
2009-12-01
7.0
7
1
 35,000 
 2,000 
2009-06-01
0.6667
2
3
 10,785 
 3,893 
2008-12-01
8.0
8
1
 35,500 
 2,000 
2008-09-01
0.8571
6
7
 17,981 
 31,000 
2008-06-01
0.3333
1
3
 748.00 
 1,078 
2007-12-01
2.6667
8
3
 38,500 
 9,000 
2007-09-01
0.6
6
10
 21,293 
 47,000 
2007-06-01
0.375
3
8
 15,000 
 69,190 
2006-12-01
6.0
6
1
 30,000 
 50,000 
2006-06-01
0.5
1
2
 1,498 
 1,498 
2006-03-01
0.4
10
25
 457,500 
 582,180 
2005-09-01
0.7333
11
15
 83,637 
 185,984 
2005-06-01
0.5
7
14
 79,142 
 158,284 
2005-03-01
1.0
1
1
 1,000.00 
 1,425 
2004-12-01
7.0
7
1
 50,000 
 0.00 
2004-09-01
0.8125
13
16
 32,277 
 41,075 
2004-06-01
0.3333
1
3
 40,000 
 80,000 
2003-12-01
3.0
12
4
 73,334 
 130,000 
2003-09-01
0.6923
9
13
 97,846 
 166,876 

Bio Techne Notable Stakeholders

A Bio Techne stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Techne often face trade-offs trying to please all of them. Bio Techne's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Techne's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Charles KummethCEO and President and DirectorProfile
MD MBAPresident GenomicsProfile
William GeistPresident SegmentProfile
James CPAExecutive CFOProfile
James HippelCFO and VP of Fin.Profile
Gary LathamVP CTOProfile
Robert GavinSr. VP of Protein Platforms DivisionProfile
Shane BohnenGeneral VPProfile
Lynne HohlfeldSenior DivisionProfile
Luca CicchettiManaging DirectorProfile
Brenda JDGen VPProfile
Martin WirtzSenior DevelopmentProfile
Cheryl BethuneSenior OfficerProfile
David CFASenior DevelopmentProfile
Gerry AndrosVice MarketingProfile
Bernie AndrussSenior DivisionProfile
Kim KeldermanPres GenomicsProfile
Evett KrukaSenior DivisionProfile
Dylan MalayterSenior DivisionProfile
David ClairIR Contact OfficerProfile
Kevin SmythSenior OfficerProfile
Steven SilvermanSenior ExperienceProfile
Brenda EversonSenior OfficerProfile
Steve CrouseSenior DivisionProfile

About Bio Techne Management Performance

The success or failure of an entity such as Bio Techne Corp often depends on how effective the management is. Bio Techne management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.12  0.16 
Return On Capital Employed 0.09  0.09 
Return On Assets 0.07  0.07 
Return On Equity 0.09  0.09 

Bio Techne Workforce Analysis

Traditionally, organizations such as Bio Techne use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Techne within its industry.

Bio Techne Manpower Efficiency

Return on Bio Techne Manpower

Revenue Per Employee373.9K
Revenue Per Executive48.3M
Net Income Per Employee54.2K
Net Income Per Executive7M
Working Capital Per Employee147.8K
Working Capital Per Executive19.1M

Complementary Tools for Bio Stock analysis

When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators